$721 M

DRNA Mkt cap, 22-Jun-2018

$1.2 M

Dicerna Pharmaceuticals Revenue FY, 2017
Dicerna Pharmaceuticals Net income (FY, 2017)-60 M
Dicerna Pharmaceuticals EBIT (FY, 2017)-60.6 M
Dicerna Pharmaceuticals Cash, 31-Dec-201768.8 M

Dicerna Pharmaceuticals Financials

Dicerna Pharmaceuticals Income Statement

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017

Revenue

184 k295 k1.2 m

Revenue growth, %

60%

R&D expense

29.5 m44 m41.7 m37 m

General and administrative expense

15.6 m19.2 m18.3 m25.9 m

Operating expense total

45.1 m63.2 m60 m62.9 m

EBIT

(45.1 m)(63 m)(59.7 m)(60.6 m)

EBIT margin, %

(34254%)(20254%)(5126%)

Interest expense

199 k199 k199 k

Interest income

63 k188 k235 k539 k

Net Income

(47.9 m)(62.8 m)(59.5 m)(60 m)

Quarterly

USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Revenue

184 k184 k184 k162 k133 k252 k474 k

R&D expense

5.3 m6.8 m7.5 m8.7 m11.9 m12.1 m11.3 m11 m10.1 m8.9 m9.3 m9 m

General and administrative expense

2.8 m4.4 m3.7 m5.4 m4.5 m4.9 m4.5 m4.7 m4.3 m5.5 m6.3 m6.7 m

Operating expense total

8.1 m11.2 m11.2 m14.1 m16.4 m17 m15.7 m15.7 m14.4 m14.4 m15.6 m15.7 m

EBIT

(8.1 m)(11.2 m)(11.2 m)(14.1 m)(16.2 m)(17 m)(15.7 m)(15.7 m)(14.2 m)(14.2 m)(15.4 m)(15.2 m)

EBIT margin, %

(8810%)(9239%)(8526%)(8788%)(10706%)(6098%)(3209%)

Interest expense

157 k42 k157 k42 k

Interest income

4 k8 k21 k53 k34 k55 k55 k66 k61 k38 k143 k179 k

Net Income

(10.8 m)(11.4 m)(11.2 m)(14.1 m)(16.2 m)(16.9 m)(15.7 m)(15.6 m)(14.2 m)(14.2 m)(15.2 m)(15 m)

Dicerna Pharmaceuticals Balance Sheet

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017

Cash

26.1 m56.1 m20.9 m68.8 m

Accounts Receivable

254.7 m805.4 k

Inventories

1.2 m1.5 m2 m

Current Assets

97.3 m96.1 m47.8 m118.6 m

PP&E

2.2 m2.7 m2.2 m1.5 m

Total Assets

103.6 m100 m51.3 m120.9 m

Accounts Payable

1.2 m2.6 m4.3 m4.9 m

Short-term debt

4.6 m

Current Liabilities

5.2 m9 m10 m16.6 m

Non-Current Liabilities

106 k106 k

Total Liabilities

5.3 m9.1 m10 m19.6 m

Additional Paid-in Capital

231.7 m287.3 m297 m417 m

Retained Earnings

(133.4 m)(196.2 m)(255.8 m)(315.8 m)

Total Equity

91 m41.2 m101.2 m

Financial Leverage

1.1 x1.2 x1.2 x

Quarterly

USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Cash

133.8 m77.7 m31.8 m22.6 m25.9 m52.9 m27.6 m29.2 m32.5 m22.9 m38.8 m31 m

Current Assets

134.7 m101.3 m93.7 m89.1 m96.7 m95.7 m81.8 m70.7 m59.4 m36.2 m91.7 m79.8 m

PP&E

911 k1.5 m1.9 m2.3 m2.6 m2.7 m2.5 m2.5 m2.4 m2 m1.8 m1.7 m

Total Assets

135.9 m124.2 m116 m92.7 m127.7 m113.6 m85.5 m74.3 m62.9 m39.4 m94.7 m82.7 m

Accounts Payable

715 k1.1 m1.2 m1.8 m1.6 m1.4 m2.4 m3.2 m3.7 m4.1 m4.1 m5.4 m

Short-term debt

3.8 m

Current Liabilities

6.5 m4 m5.1 m6 m9 m9.4 m7.4 m9.4 m9.8 m10.3 m9.6 m10.5 m

Non-Current Liabilities

106 k106 k106 k106 k

Total Debt

3.8 m

Total Liabilities

6.5 m4 m5.2 m6 m9 m9.4 m7.4 m9.4 m9.8 m10.3 m9.6 m10.5 m

Additional Paid-in Capital

225.6 m228 m229.6 m234.2 m282.3 m284.9 m290.1 m292.5 m294.9 m299 m298.4 m296.4 m

Retained Earnings

(96.3 m)(107.8 m)(118.8 m)(147.5 m)(163.7 m)(180.6 m)(211.9 m)(227.6 m)(241.7 m)(270 m)(285.2 m)(300.2 m)

Total Equity

86.7 m118.7 m104.3 m78.2 m65 m53.1 m29.1 m13.3 m

Financial Leverage

1.1 x1.1 x1.1 x1.1 x1.1 x1.2 x1.4 x7.1 x

Dicerna Pharmaceuticals Cash Flow

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(47.9 m)(62.8 m)(59.5 m)(60 m)

Depreciation and Amortization

848 k727 k840 k778 k

Accounts Receivable

(15.1 m)

Inventories

(44.3 m)

Accounts Payable

(97 k)1.4 m1.6 m626 k

Cash From Operating Activities

(20.5 m)30 m(48.7 m)(45.3 m)

Purchases of PP&E

(2 m)(1.1 m)(449 k)(133 k)

Cash From Investing Activities

(75.8 m)33 m13 m(19.5 m)

Long-term Borrowings

(5 m)

Cash From Financing Activities

90 m45.8 m534 k112.7 m

Interest Paid

194 k194 k194 k

Quarterly

USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(10.8 m)(11.4 m)(11.2 m)(14.1 m)(16.2 m)(16.9 m)(15.7 m)(15.6 m)(14.2 m)(14.2 m)

Depreciation and Amortization

164 k

Accounts Payable

1.1 m1.2 m525 k1.6 m1.4 m2.4 m3.2 m3.7 m4.1 m

Cash From Operating Activities

(10.6 m)

Purchases of PP&E

(434 k)

Cash From Investing Activities

7.1 m

Cash From Financing Activities

149 k

Dicerna Pharmaceuticals Ratios

USDY, 2017

Revenue/Employee

25 k

Financial Leverage

1.2 x
Report incorrect company information